Description
Introduction
Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. There are various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as; cancer targeted therapies.
The global cancer biological therapy market is expected to reach USD 82,276.8 million by 2023 at a CAGR of 4.7% during the forecasted period.
The global cancer biological therapy market is segmented on the basis of phases, types, end users and regions. On the basis of phases, the market is segmented into phase I, phase II and phase III. In stage I & II the real impact of these therapies is seen and giving a success rate of 35% in Phase 1 and 20% in Phase II. The success rate of phase I is 35%.
On the basis on types, the global cancer biological therapy market is segmented into monoclonal antibodies, cancer growth blockers, interferons, interleukins, gene therapy, targeted drug delivery, colony stimulating factor, cancer vaccines and others. Monoclonal antibodies accounted for the largest market share of the global cancer biological therapy market. Colony stimulating factor is the fastest growing market at a CAGR of 5.2% during the forecasted period.
On the basis on end users, hospitals & clinics dominates the global cancer biological therapy market. Registering USD 26,790.6 million in 2016 and expected to reach at USD 38,471.9 million by 2023 at the rate of 4.4 % from 2016-2023.
On the basis of regions, the market is segmented into North America, Europe, Asia-Pacific and the Middle East & Africa. North America has the dominating market for cancer biological therapy. The cancer biological therapy market for North America is estimated at USD 19,481.2 million in 2016 and expected to reach by USD 29,516.9 million by 2023 at a fastest CAGR of 5.10%.
Key Players
The leading market players in the global cancer biological therapy market include Merck Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Bristol-Myers Squibb, Celgene, ELI Lilly and Company, EnGeneIC, and Pfizer
Study objectives
• To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global cancer biological therapy market
• To provide insights about factors influencing and affecting the market growth
• To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
• To provide historical and forecast revenue of the market segments based on channels, applications, and regions for the global cancer biological therapy market.
• To provide strategic profiling of key players in the market, and comprehensively analysing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economical factors that influences the global cancer biological therapy market
• To provide detailed analysis of the value chain and supply chain of the global cancer biological therapy market
Target Audience
• Pharmaceutical Companies
• Pharmaceutical Suppliers
• Cancer Research Organizations
• Potential Investors
• Key Executive (CEO and COO) and Strategy Growth Manager
• Reaserch Companies
Key Findings
• North America accounted for the largest market share in the global cancer biological therapy market, USD 19,481.2 million in 2016 and expected to reach by USD 29,516.9 million by 2023 at a fastest CAGR of 5.10%
• Colony stimulating factor is the fastest growing segment with a CAGR of and 5.2% in the global cancer biological therapy market, by types
• Hospitals and clinics is contributing remarkable share in the market registering 47.8% in the global cancer biological therapy market, by end users in 2016
The reports also covers regional analysis
• North America
o US
o Canada
• Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.5 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing Cancer Survival Rate
4.2.2 Growing Demand for Advanced Therapies
4.2.3 Less Number of Side Effects as Compared to Conventional Treatment Methods
4.2.4 Growth of Cancer Healthcare Facilities in Emerging Countries
4.2.5 Changing Lifestyle and Increasing Smoking Population in Middle East & Africa
4.3 Restraints
4.3.1 High cost of Cancer Biological Therapy
4.4 Opportunities
4.4.1 UnTapped Types of Cancers
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining power of suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
6 Global Cancer Biological Therapy Market, by phases
6.1 Introduction
6.2 Phases
7 Global Cancer Biological Therapy Market, by Application
7.1 Introduction
7.2 Monoclonal Antibodies
7.3 Interferons
7.4 Interleukins
7.5 Cancer growth inhibitors
7.6 Gene Therapy
7.7 Colony-Stimulating Factors
8 Global Cancer Biological Therapy Market, by End Users
8.1 Introduction
8.2 Hospitals & Clinics
8.3 Cancer Research Centers
8.4 Laboratories
9 Global Cancer Biological Therapy Market, by Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 U.K.
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Republic of Korea
9.4.5 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
12 Competitive Landscape
12.1 Company Share Analysis
13 Company Profiles
13.1 Amgen Inc.
13.1.1 Company Overview
13.1.2 Product/Business Overview
13.1.3 Adherium Health: Financials
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.2 Bristol-Myers Squibb
13.2.1 Company Overview
13.2.2 Product overview
13.2.3 Financial Overview
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.3 Celgene Corporation
13.3.1 Company Overview
13.3.2 Product Overview
13.3.3 Financial Overview
13.3.4 Key Development
13.3.5 SWOT Analysis
13.4 ELI Lilly and Company
13.4.1 Company Overview
13.4.2 Product Overview
13.4.3 Financial Overview
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.5 EnGeneIC Ltd
13.5.1 Company Overview
13.5.2 Product overview
13.5.3 Financial Overview
13.5.4 Key Developments
13.5.5 SWOT Analysis
TABLE 1 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 2 MONOCLONAL ANTIBODIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2014-2023 (USD MILLION)
TABLE 3 INTERFERONS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION)
TABLE 4 INTERLEUKINS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION)
TABLE 5 CANCER GROWTH INHIBITORS FOR CANCER BIOLOGIC THERAPY MARKET, BY REGION 2014-2023 (USD MILLION)
TABLE 6 GENE THERAPY FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION)
TABLE 7 COLONY STIMULATING FACTOR FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION)
TABLE 8 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 9 HOSPITALS & CLINICS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION)
TABLE 10 CANCER RESEARCH CENTERS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION)
TABLE 11 LABORATORIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION)
TABLE 12 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION)
TABLE 13 NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2014-2023 (USD MILLION)
TABLE 14 NORTH AMERICA BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 15 NORTH AMERICA BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 16 U.S. CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 17 U.S. CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 18 CANADA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 19 CANADA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 20 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2014-2023 (USD MILLION)
TABLE 21 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 22 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 23 GERMANY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 24 GERMANY CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 25 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 26 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 27 U.K. CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 28 U.K. CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 29 ITALY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 30 ITALY CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 31 SPAIN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 32 SPAIN CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 33 ROE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 34 ROE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 35 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2014-2023 (USD MILLION)
TABLE 36 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 37 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 38 JAPAN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 39 JAPAN CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 40 CHINA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 41 CHINA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 42 INDIA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 43 INDIA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 44 REPUBLIC OF KOREA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 45 REPUBLIC OF KOREA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 46 ROA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 47 ROA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2014-2023 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 51 MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 52 MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 53 AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2014-2023 (USD MILLION)
TABLE 54 AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2014-2023 (USD MILLION)
TABLE 55 AMGEN INC.: KEY DEVELOPMENT
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET DYNAMICS FOR GLOBAL CANCER BIOLOGICAL THERAPY MARKET
FIGURE 3 ATTRITION RATE OF PHASE III CLINICAL TRIALS IN EUROPE, 2012 (%)
FIGURE 4 CANCER BIOLOGICAL THERAPY SUCCESS RATES IN VARIOUS PHASES OF CLINICAL TRIALS
FIGURE 5 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY TYPE 2016
FIGURE 6 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY END USER, 2016
FIGURE 7 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY REGION, 2016
FIGURE 8 NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2016
FIGURE 9 EUROPE CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2016
FIGURE 10 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2016
FIGURE 11 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2016
FIGURE 12 QATAR: CANCER INCIDENCE AND MORTALITY RATES (%)
FIGURE 13 UAE: CANCER INCIDENCE AND MORTALITY RATES (%)
FIGURE 14 KUWAIT: CANCER INCIDENCE AND MORTALITY RATES (%)
FIGURE 15 BAHRAIN: CANCER INCIDENCE AND MORTALITY RATES (%)
FIGURE 16 OMAN: CANCER INCIDENCE AND MORTALITY RATES (%)
FIGURE 17 SAUDI ARABIA: CANCER INCIDENCE AND MORTALITY RATES (%)
FIGURE 18 GLOBAL CANCER BIOLOGICAL THERAPY MARKET: COMPANY SHARE ANALYSIS, 2015 (%)
FIGURE 19 AMGEN INC.: KEY FINANCIALS
FIGURE 20 AMGEN INC.: SEGMENTAL REVENUE
FIGURE 21 AMGEN INC.: GEOGRAPHICAL REVENUE
FIGURE 22 BRISTOL-MYERS SQUIBB.: KEY FINANCIALS
FIGURE 23 BRISTOL-MYERS SQUIBB.: SEGMENTAL REVENUE
FIGURE 24 BRISTOL-MYERS SQUIBB: GEOGRAPHICAL REVENUE
FIGURE 25 CELGENE CORPORATION.: KEY FINANCIALS
FIGURE 26 CELGENE CORPORATION.: SEGMENTAL REVENUE
FIGURE 27 CELGENE CORPORATION: GEOGRAPHICAL REVENUE
FIGURE 28 ELI LILLY AND COMPANY.: KEY FINANCIALS
FIGURE 29 ELI LILLY AND COMPANY.: SEGMENTAL REVENUE
FIGURE 30 ELI LILLY AND COMPANY: GEOGRAPHICAL REVENUE
FIGURE 31 F. HOFFMANN-LA ROCHE AG: FINANCIAL REVENUE
FIGURE 32 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE
FIGURE 33 F. HOFFMANN-LA ROCHE AG: GEOGRPAHICAL REVENUE
FIGURE 34 MERCK & CO., INC: FINANCIAL REVENUE
FIGURE 35 MERCK & CO., INC: SEGMENTAL REVENUE
FIGURE 36 MERCK & CO., INC: GEOGRPAHICAL REVENUE
FIGURE 37 NOVARTIS: FINANCIAL REVENUE
FIGURE 38 NOVARTIS: SEGMENTAL REVENUE
FIGURE 39 NOVARTIS: GEOGRPAHICAL REVENUE
FIGURE 40 PFIZER INC: FINANCIAL REVENUE
FIGURE 41 PFIZER INC: SEGMENTAL REVENUE
FIGURE 42 PFIZER INC: GEOGRPAHICAL REVENUE
